Tarian Pharma develops topical medications aimed at preventing radiation-induced dermatitis in breast cancer patients undergoing treatment with panitumumab or cetuximab. Their products address the significant issue of severe skin toxicities, enhancing patient comfort and treatment adherence during cancer therapy.
Funding
Funding not disclosed
Founders
Product
Problem
Breast cancer patients undergoing treatment with panitumumab or cetuximab often experience radiation-induced dermatitis, a severe skin toxicity that can negatively impact their comfort and adherence to therapy. This condition presents a significant challenge in oncodermatology, requiring effective preventative measures.
Solution
Tarian Pharma develops innovative, potent topical medications specifically designed to prevent radiation-induced dermatitis in cancer patients. These products aim to mitigate the severe skin toxicities associated with treatments like panitumumab and cetuximab. By focusing on prevention, Tarian Pharma seeks to improve patient comfort, enhance treatment adherence, and ultimately support better outcomes during cancer therapy. The company's approach addresses a high unmet need in oncodermatology supportive care.
Target Audience
The primary target audience includes breast cancer patients undergoing treatment with panitumumab or cetuximab, as well as oncologists and dermatologists seeking to minimize skin toxicities in their patients.
Features
- Topical formulations designed for ease of application.
- Focus on preventing the onset of radiation-induced dermatitis.
- Products intended to reduce the severity of skin toxicities.
- Aims to improve patient comfort during cancer treatment.